(UroToday.com) The 2025 American Society of Clinical Oncology (ASCO) Annual Meeting held in Chicago, IL between May 30 and June 3 was host to the Poster Session: Genitourinary Cancer - Prostate, ...

Regeneron Pharmaceuticals Inc. is adding to its obesity pipeline by in-licensing Hansoh Biomedical Co. Ltd.’s phase III dual ...

Eli Lilly is counting on Camurus and its long-acting delivery technology to help take its portfolio of obesity and diabetes drugs to the next level with a licensing deal worth up to $870 million.

At the same time, GLP-1 inhibits the release of glucagon, a hormone that increases blood ... GLP-1 reduces the feeling of hunger via specific satiety centers in the brain. GIP also appears to ...

Agonists and antagonists of the GIP receptor influence body weight ... At the same time, GLP-1 inhibits the release of glucagon, a hormone that increases blood sugar levels. In addition, GLP ...

Regeneron isn’t the only Big Pharma to spot potential in Hansoh’s obesity pipeline. Merck & Co. ended last year paying $112 ...

Reducing the release of glucagon ... and prescribed either the GLP-1 receptor agonist semaglutide or the dual GLP-1/GIP agonist tirzepatide. Of the participants, 60% (n = 120) were treated ...

As well as regulating the release of insulin in response to food ... pharmacologically activates two metabolic receptors, GIP and GLP-1, which have both overlapping and non-overlapping expression ...

Agonists and antagonists of the GIP receptor influence body weight ... At the same time, GLP-1 inhibits the release of glucagon, a hormone that increases blood sugar levels. In addition, GLP ...